The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors-Global Market Insights and Sales Trends 2025

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1819622

No of Pages : 94

Ask Your Query
Synopsis
The Dipeptidyl Peptidase IV (DPP-IV) inhibitors market refers to the industry that focuses on the production and distribution of medications known as DPP-IV inhibitors. DPP-IV inhibitors are a class of oral antidiabetic drugs used in the treatment of type 2 diabetes mellitus. They work by inhibiting the action of the enzyme DPP-IV, which leads to increased levels of incretin hormones and improved glycemic control.

The global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market size is expected to reach US$ 18170 million by 2029, growing at a CAGR of 7.1% from 2023 to 2029. The market is mainly driven by the significant applications of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market. Sitagliptin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Vildagliptin segment is estimated at % CAGR for the next seven-year period.
The DPP-IV inhibitors market is a segment within the broader pharmaceutical industry, specifically in the field of diabetes management. It involves the development, manufacturing, and distribution of DPP-IV inhibitor medications used to treat type 2 diabetes.
The DPP-IV inhibitors market is influenced by factors such as the increasing prevalence of type 2 diabetes worldwide, the rising demand for effective oral antidiabetic medications, and the growing emphasis on diabetes management and control. Additionally, factors such as an aging population, sedentary lifestyles, and changes in dietary habits contribute to the market's growth.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Dipeptidyl Peptidase IV (DPP-IV) Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors covered in this report include AstraZeneca, Boehringer, Eli Lilly, Merck, Mitsubishi Tanabe Pharma, Novartis and Takeda, etc.
The global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Boehringer
Eli Lilly
Merck
Mitsubishi Tanabe Pharma
Novartis
Takeda
Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, Segment by Type:
Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Others
Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Overview
1.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Overview
1.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Segment by Type
1.2.1 Sitagliptin
1.2.2 Vildagliptin
1.2.3 Saxagliptin
1.2.4 Linagliptin
1.2.5 Others
1.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size by Type
1.3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Overview by Type (2018-2029)
1.3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size Review by Type (2018-2023)
1.3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Type (2018-2023)
2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Competition by Company
2.1 Global Top Players by Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (2018-2023)
2.2 Global Top Players by Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2018-2023)
2.3 Global Top Players by Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Price (2018-2023)
2.4 Global Top Manufacturers Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Competitive Situation and Trends
2.5.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Dipeptidyl Peptidase IV (DPP-IV) Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market
2.8 Key Manufacturers Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Status and Outlook by Region
3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size by Region
3.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Region (2018-2023)
3.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Region (2018-2023)
3.2.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Region
3.3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Region (2024-2029)
3.3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Region (2024-2029)
3.3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Application
4.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Segment by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size by Application
4.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Overview by Application (2018-2029)
4.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size Review by Application (2018-2023)
4.2.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Breakdown by Application (2018-2023)
5 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Country
5.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size by Country
5.1.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2018-2023)
5.1.3 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2018-2023)
5.2 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Country
5.2.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2024-2029)
5.2.2 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2024-2029)
6 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Country
6.1 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size by Country
6.1.1 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2018-2023)
6.1.3 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2018-2023)
6.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Country
6.2.1 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2024-2029)
6.2.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2024-2029)
7 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Region
7.1 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Region (2024-2029)
8 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Country
8.1 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size by Country
8.1.1 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2018-2023)
8.1.3 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2018-2023)
8.2 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2024-2029)
8.2.2 Latin America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2024-2029)
9 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Country
9.1 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Boehringer
10.2.1 Boehringer Company Information
10.2.2 Boehringer Introduction and Business Overview
10.2.3 Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Products Offered
10.2.5 Boehringer Recent Development
10.3 Eli Lilly
10.3.1 Eli Lilly Company Information
10.3.2 Eli Lilly Introduction and Business Overview
10.3.3 Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Products Offered
10.3.5 Eli Lilly Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Introduction and Business Overview
10.4.3 Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Products Offered
10.4.5 Merck Recent Development
10.5 Mitsubishi Tanabe Pharma
10.5.1 Mitsubishi Tanabe Pharma Company Information
10.5.2 Mitsubishi Tanabe Pharma Introduction and Business Overview
10.5.3 Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Products Offered
10.5.5 Mitsubishi Tanabe Pharma Recent Development
10.6 Novartis
10.6.1 Novartis Company Information
10.6.2 Novartis Introduction and Business Overview
10.6.3 Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Products Offered
10.6.5 Novartis Recent Development
10.7 Takeda
10.7.1 Takeda Company Information
10.7.2 Takeda Introduction and Business Overview
10.7.3 Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Products Offered
10.7.5 Takeda Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industrial Chain Analysis
11.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Dynamics
11.4.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Trends
11.4.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Drivers
11.4.3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Challenges
11.4.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Distributors
12.3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock